Neuroscience, cancer, and pain - these are the three areas where Neuromics products are most prevalent. Last month, researchers from New York University published a study at the intersection of these three fields, using a neural cell type to explore the mechanisms of pain in oral cancer.
Image: TRPV4 is functionally expressed in Neuromics human Schwann cells. Expression is confirmed using TRPV4 agonist GSK1016790A.
Oral cancer is known to often cause a lot of pain when the lesion is touched or pressured, but the cause of this pain is not well understood. When looking at some of the mechanisms of this pain, the scientists employed our primary human Schwann cells (cat. HMP303). The investigation focused on the expression of TRPV4 in Schwann cells, including our Schwann cells. They found that TRPV4 inhibition reduced pain in mouse models, suggesting TRPV4 from activated Schwann cells is a major source of pain in oral cancer. You can read the full study here.
In other news, investigators from the University of Georgia published a protocol to isolate fibro/adipogenic progenitors (FAPs) from mouse using magnetic-activated cell sorting (MACS). FAPs are commonly used in muscle disorder and regeneration research. In their protocol, the FAPs are cultured with Neuromics FBS. Learn more.
Bottom Image: Immunostaining of mouse fibro/adipogenic progenitors (FAPs) cultured using Neuromics FBS.
You can explore all publications using Neuromics human cells, FBS, antibodies, and more here.
